Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Protalix BioTherapeutics, Inc. Common Stock

PLX

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Last trade $2.88
Day change -$0.15 (-4.95%)
Day range $2.87 – $3.07
Volume 619,398
Market cap $255M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$255.49M
Price / earnings
12.43×
Price / book
3.17×
Price / sales
3.02×
EV / sales
2.76×
EV / EBITDA
8.7×

Profitability

Earnings per share
$0.24
Return on assets
17.38%
Return on equity
25.51%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.27×
Quick ratio
2.14×
Cash ratio
0.73×

Cash flow

Price / cash flow
14.55×
Price / free cash flow
16.96×
Free cash flow
$15.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PLX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$21.93M$19.9M$33.75M$9.12M$17.85M$15.66M$10.11M$18.22M
Cost of revenue$7.88M$7.76M$4.13M$4.62M$8.32M$5.87M$8.18M$3.89M
Gross profit$14.05M$12.13M$29.62M$4.5M$9.53M$9.79M$1.93M$14.33M
Selling, general and administrative$3.08M$3.11M$3.05M$3.53M$2.93M$2.62M$2.6M$3M
Research and development$6.92M$4.35M$5.43M$5.64M$4.47M$5.99M$3.48M$4.12M
Total operating expenses$10M$7.46M$8.48M$9.16M$7.4M$8.62M$6.08M$7.12M
Operating income$4.05M$4.67M$21.15M-$4.66M$2.13M$1.17M-$4.15M$7.21M
Interest expense-$24K-$494K-$193K-$383K-$180K-$783K-$6K-$6K
Income before taxes$4.62M$4.86M$21.14M-$4.78M$2.24M$661K-$3.73M$7.32M
Income taxes$661K$1.08M$2.82M$728K-$116K$497K-$113K$822K
Net income$3.96M$3.78M$18.32M-$5.5M$2.36M$164K-$3.62M$6.49M
Net income attributable to common shareholders$3.96M$3.78M$18.32M-$5.5M$2.36M$164K-$3.62M$6.49M
EBITDA$4.47M$5.08M$21.55M-$4.27M$2.5M$1.53M-$3.8M$7.54M
Basic earnings per share$0.05$0.05$0.23-$0.07$0.03$0.00-$0.05$0.09
Diluted earnings per share$0.05$0.05$0.22-$0.07$0.03$0.00-$0.05$0.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Protalix (PLX) Q2 2026 Earnings Call Transcript

Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.

GlobeNewswire Inc.

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

The European Commission has approved a new every-4-weeks dosing regimen (2mg/kg) for Elfabrio® (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. This approval extends the infusion interval from every 2 weeks, reducing treatment burden for patients and healthcare systems. Protalix is entitled to a $25 million regulatory milestone payment from Chiesi. The FDA-approved dosing in the US remains unchanged at 1mg/kg every 2 weeks.

GlobeNewswire Inc.

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 20, 20191-for-10reverse split